Avalo amends 8K to restate AlmataBio 2023 financials; net loss up $153K

Avalo Therapeutics, Inc.

Restated AlmataBio net loss for April 28–Dec 31, 2023 to $812K from $659K, a $153K increase.
R&D expense corrected upward by $135K to $663K; G&A expense up $18K to $149K.
Restatement had no cash flow impact; cash and equivalents remained $1.767M at Dec 31, 2023.
Previously issued financials for AlmataBio are superseded by this restated filing.
Acquisition of AlmataBio by Avalo closed on March 27, 2024; this is Amendment No. 2 to the original 8-K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.